<DOC>
	<DOCNO>NCT00478075</DOCNO>
	<brief_summary>RATIONALE : Radioactive drug , samarium Sm 153 lexidronam pentasodium , may carry radiation directly cancer cell harm normal cell . Bortezomib may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Bortezomib may also make cancer cell sensitive radiation therapy . Giving samarium Sm 153 lexidronam pentasodium together bortezomib may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose bortezomib give together samarium Sm 153 lexidronam pentasodium see well work treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Samarium Sm 153 Lexidronam Pentasodium Bortezomib Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose bortezomib give together samarium Sm 153 lexidronam pentasodium patient recurrent refractory multiple myeloma . ( Phase I ) - Determine safety tolerability regimen patient . ( Phase II ) - Determine hematologic response rate patient treat regimen . ( Phase II ) Secondary - Determine rate serum immunoglobulin light chain reduction patient treat regimen . - Assess vivo toxicity regimen progenitor cell measure complete blood cell count micronucleated reticulocyte count patient . OUTLINE : This phase I , pilot , open-label , dose-escalation study bortezomib follow phase II study . - Phase I : Patients receive samarium Sm 153 lexidronam pentasodium IV 1 minute day 1 bortezomib IV 3-5 second day 2 5 . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . - Phase II : Patients receive samarium Sm 153 lexidronam pentasodium phase I bortezomib MTD determine phase I . Patients undergo blood sample collection baseline day 1-6 correlative study . Samples analyze micronucleated reticulocyte count immunoglobulin free light chain ratio determine early effect treatment . After completion study treatment , patient follow weekly 7 week , monthly 3 month every 3 month total 3 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Relapsed refractory disease Measurable evaluable disease define least 1 follow : Serum monoclonal protein ≥ 1.0 g protein electrophoresis Monoclonal protein ≥ 200 mg 24hour urine electrophoresis Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥ 30 % ( evaluable disease ) Previously treat disease No limit prior therapy provide adequate residual organ function Must undergone hematopoietic stem cell collection ( transplant candidate ) OR consider hematopoietic stem cell transplant candidate PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 ( ECOG PS 3 allow secondary pain ) Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) ANC ≥ 1,000/mm^3 Creatinine ≤ 3 mg/dL Calcium ≤ 15 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week completion study therapy No impending long bone fracture No active malignancy except nonmelanoma skin cancer , carcinoma situ cervix , breast cancer No uncontrolled infection No known hypersensitivity component study drug No comorbidity would preclude study participation PRIOR CONCURRENT THERAPY : Recovered prior surgery , radiotherapy , antineoplastic therapy No prior samarium Sm 153 lexidronam pentasodium strontium chloride Sr 89 At least 3 week since prior myelosuppressive agent At least 2 week since prior nonmyelosuppressive agent ( e.g. , thalidomide ) At least 2 week since prior concurrent highdose corticosteroid Chronic steroid ( maximum dose 20 mg/day prednisone equivalent ) allow disorder myeloma ( i.e. , adrenal insufficiency rheumatoid arthritis ) At least 30 day since prior concurrent investigational therapy No concurrent external beam radiotherapy No concurrent cytotoxic chemotherapy No concurrent systemic antineoplastic therapy include , limited , follow : Immunotherapy Hormonal therapy Monoclonal antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>